Analysts’ Top Healthcare Picks: Bausch + Lomb Corporation (BLCO), Insulet (PODD)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bausch + Lomb Corporation (BLCO – Research Report), Insulet (PODD – Research Report) and NewAmsterdam Pharma Company (NAMS – Research Report) with bullish sentiments.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Bausch + Lomb Corporation (BLCO)
RBC Capital analyst Douglas Miehm maintained a Buy rating on Bausch + Lomb Corporation today and set a price target of $21.00. The company’s shares closed last Wednesday at $17.67.
According to TipRanks.com, Miehm is a 4-star analyst with an average return of
Currently, the analyst consensus on Bausch + Lomb Corporation is a Moderate Buy with an average price target of $18.56, which is a 10.7% upside from current levels. In a report released today, Citi also maintained a Buy rating on the stock with a $21.00 price target.
See the top stocks recommended by analysts >>
Insulet (PODD)
In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Insulet, with a price target of $380.00. The company’s shares closed last Wednesday at $258.07.
According to TipRanks.com, Chadha is a 3-star analyst with an average return of
Insulet has an analyst consensus of Strong Buy, with a price target consensus of $366.18, a 37.7% upside from current levels. In a report released today, TipRanks – DeepSeek also upgraded the stock to Buy with a $285.00 price target.
NewAmsterdam Pharma Company (NAMS)
Guggenheim analyst Debjit Chattopadhyay maintained a Buy rating on NewAmsterdam Pharma Company yesterday and set a price target of $45.00. The company’s shares closed last Wednesday at $35.76.
According to TipRanks.com, Chattopadhyay is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for NewAmsterdam Pharma Company with a $47.38 average price target, representing a 34.3% upside. In a report issued on February 6, Stifel Nicolaus also maintained a Buy rating on the stock with a $50.00 price target.
